^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colorectal Cancer

    Related cancers:
    10h
    Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival. (PubMed, Clin Epigenetics)
    Protein EpiScores are significantly associated with CRC survival. These findings highlight biological pathways underlying CRC prognosis and support the utility of Protein EpiScores for modeling survivorship.
    Journal
    |
    LGALS3 (Galectin 3) • LGALS3BP (Lectin galactoside-binding soluble 3-binding protein)
    11h
    Intensified Chemotherapy in CRC After Resection of Liver Metastases (clinicaltrials.gov)
    P2/3, N=124, Completed, Institut du Cancer de Montpellier - Val d'Aurelle | Phase classification: P3 --> P2/3
    Phase classification
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    11h
    KontRASt-03: Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • Mekinist (trametinib) • Kisqali (ribociclib) • opnurasib (JDQ443)
    11h
    Protective Effect of N-Acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=46, Completed, Tanta University
    New trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    13h
    GYNERECT: Evaluation of Gynecological and Sexual Sequelae (clinicaltrials.gov)
    P=N/A, N=15, Not yet recruiting, University Hospital, Rouen
    New trial
    13h
    Modified Title Project 4: Effect of Meal Timing During Cancer Treatment in Alaska Native Patients (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    14h
    Improving Care for Rural Patients With Solid Tumors (clinicaltrials.gov)
    P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    17h
    BBOpCo: Botensilimab and Balstilimab Optimization in Colorectal Cancer (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Nicholas DeVito, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    17h
    CD3+RUNX3+ lymphocyte density; an independent prognostic factor in colon and lung adenocarcinoma but not in lung squamous cell carcinoma. (PubMed, Sci Rep)
    In COAD, a subset of patients in stage II/III with CD3+RUNX3+high/CD8 + high may be spared adjuvant treatment due to excellent prognosis. However, further studies are needed to confirm and elucidate the protective role of CD3+RUNX3+ cells in COAD and LUAD.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3) • RUNX3 (RUNX Family Transcription Factor 3)
    17h
    Current understanding and management of brain metastasis from colorectal cancer. A review. (PubMed, J Visc Surg)
    BMCRC is challenging because of its rarity and complex management. Recent advances in systemic therapies and diagnostic techniques have improved patient outcomes. Future research should focus on novel therapeutic approaches and biomarker validation to enhance early detection and personalize treatment strategies.
    Review • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    17h
    Oral immunization with Listeria monocytogenes vaccine enhances immunotherapy for protective immunity in murine models of colorectal cancer. (PubMed, J Immunother Cancer)
    Oral Lm-based cancer vaccines targeting CRC elicit robust, widely disseminated, and persistent tumor-specific immune responses in mice. These vaccines limit CRC development when administered prophylactically and provide tumor control when administered therapeutically with ICI. Thus, oral delivery of Lm-based cancer vaccines coupled with ICI may provide improved control of CRC progression in clinical application.
    Preclinical • Journal • MSi-H Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • SMAD4 (SMAD family member 4) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    MSI-H/dMMR • KRAS G12D • KRAS G12
    17h
    Berberine promotes β-catenin ubiquitination and inhibits its nuclear translocation by targeting USP22 in colorectal cancers. (PubMed, Phytomedicine)
    Notably, BBR reduced tumor stemness, exhibited substantial toxicity towards cancer stem cells and overcame the chemoresistance. Together, our finding elucidated USP22 promoted CRC progression via deubiquitinating β-catenin and promoting its subsequent nucleus translocation, and highlighted BBR was a potential therapeutic agent for CRC treatment as a novel USP22 inhibitor.
    Journal
    |
    USP22 (Ubiquitin Specific Peptidase 22)